Neil Almstead - PTC Therapeutics EVP
| PTCT Stock | USD 45.88 0.27 0.59% |
EVP
Dr. Neil Almstead, Ph.D. is Chief Technical Operations Officer of PTC Therapeutics Inc., since December 2018. Dr. Almstead was employed with PTC since 2000. He served as our Executive Vice President, Research, Pharmaceutical Operations and Technology from January 2015 to December 2018, Senior Vice President, Research and CMC from July 2008 to December 2014 and Senior Vice President, Chemistry and CMC from January 2007 to June 2008. Prior to joining PTC, Dr. Almstead served as Project Manager at Procter Gamble Company, a publicly traded consumer products company. Dr. Almstead has coauthored more than 75 publications and patents pertaining to the design and synthesis of lead candidate compounds for genetic disorders, oncology and inflammatory diseases since 2018.
| Age | 58 |
| Tenure | 7 years |
| Address | 100 Corporate Court, South Plainfield, NJ, United States, 07080 |
| Phone | 908 222 7000 |
| Web | https://www.ptcbio.com |
Neil Almstead Latest Insider Activity
Tracking and analyzing the buying and selling activities of Neil Almstead against PTC Therapeutics stock is an integral part of due diligence when investing in PTC Therapeutics. Neil Almstead insider activity provides valuable insight into whether PTC Therapeutics is net buyers or sellers over its current business cycle. Note, PTC Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell PTC Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Neil Almstead over three weeks ago Disposition of 107 shares by Neil Almstead of PTC Therapeutics at 44.5 subject to Rule 16b-3 |
PTC Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.0515) % which means that it has lost $0.0515 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (77.4012) %, meaning that it created substantial loss on money invested by shareholders. PTC Therapeutics' management efficiency ratios could be used to measure how well PTC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 0.92 in 2025, whereas Return On Tangible Assets are likely to drop (0.41) in 2025. At this time, PTC Therapeutics' Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 2.3 B in 2025, whereas Non Current Liabilities Other is likely to drop slightly above 154 K in 2025.Management Performance
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 |
PTC Therapeutics Leadership Team
Elected by the shareholders, the PTC Therapeutics' board of directors comprises two types of representatives: PTC Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of PTC. The board's role is to monitor PTC Therapeutics' management team and ensure that shareholders' interests are well served. PTC Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, PTC Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Christine Utter, Principal Financial Officer, Principal Accounting Officer, Treasurer | ||
| Christine CPA, Chief VP | ||
| Lee MD, Executive Officer | ||
| Ellen Welch, Chief Officer | ||
| FACS FACS, Chief Officer | ||
| Mark Boulding, Chief Legal Officer and Executive VP | ||
| Stuart Peltz, Co-Founder, CEO and Executive Director | ||
| Alex Kane, Investor Officer | ||
| Mark JD, Executive Officer | ||
| Linda Carter, Senior Officer | ||
| Eric Pauwels, Chief Officer | ||
| Emily Hill, Principal Financial Officer, Treasurer | ||
| FACS MD, CEO Director | ||
| Neil Almstead, Executive VP of Research, Pharmaceutical Operations and Technology | ||
| Dawn Svoronos, Director | ||
| Hege SollieZetlmayer, Senior Resources | ||
| Pierre MS, Chief Officer | ||
| Jane Baj, Vice Communications | ||
| John Baird, Chief CEO | ||
| Allan Jacobson, Co-Founder, Chairman of Scientific Advisory Board, Director and Member of Nominating and Corporate Governance Committee |
PTC Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is PTC Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -77.4 | ||||
| Return On Asset | -0.0515 | ||||
| Profit Margin | (0.50) % | ||||
| Operating Margin | (0.26) % | ||||
| Current Valuation | 2.95 B | ||||
| Shares Outstanding | 77.13 M | ||||
| Shares Owned By Insiders | 2.51 % | ||||
| Shares Owned By Institutions | 97.49 % | ||||
| Number Of Shares Shorted | 4.24 M | ||||
| Price To Earning | (5.67) X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.